Quick Order Cart

Cat. No. ARG44061

Ptger3 Knockout RAW 264.7 Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Mus musculus (Mouse)

  • Tissue Source:

    Ascites

  • Disease:

    Leukemia

The Ptger3 Knockout RAW 264.7 Cell Line is a CRISPR/Cas9-edited murine macrophage model that eliminates EP3 receptor expression, a Gi-coupled prostaglandin E2 receptor that inhibits adenylate cyclase and cAMP signaling. By disrupting EP3, this line alters key downstream mediators including PKA, ERK1/2, and NF-??B. This knockout cell line enables detailed investigation of EP3-dependent regulation of phagocytosis, cytokine secretion, and macrophage migration. It is a valuable tool for research on inflammatory disorders, pain, and cancer, particularly for validating EP3-targeted therapies and studying prostaglandin-driven immune responses.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    RAW 264.7

    Sex of Donor

    Male

    Age

    Adult

    Derived From Site

    In situ; Ascites

    Gene Name

    Ptger3

    Gene Identifier

    NCBI Gene ID 19218

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The Ptger3 Knockout RAW 264.7 Cell Line is a CRISPR/Cas9-edited knockout cell line that provides constitutive disruption of the Ptger3 gene in the RAW 264.7 mouse macrophage background. This product is supplied as a validated loss-of-function model, enabling researchers to study EP3 receptor signaling without the variability of transient knockdowns or the need for in-house genome editing. It is suitable for a wide range of functional assays in immunology and cancer biology.

RAW 264.7 cells are a well-established murine macrophage line derived from an Abelson murine leukemia virus-induced tumor in a male BALB/c mouse. They are widely employed as a model for monocyte/macrophage biology due to their robust phagocytic activity, cytokine secretion profiles, and responsiveness to Toll-like receptor ligands and inflammatory cytokines. This host background provides a physiologically relevant context for investigating prostaglandin signaling in innate immunity.

Ptger3 encodes the EP3 receptor, a G protein-coupled receptor that primarily activates Gi/o proteins, leading to inhibition of adenylate cyclase and decreased cAMP synthesis. This attenuates PKA/CREB signaling while engaging ??-arrestin-2-dependent pathways and cross-talk with PI3K/AKT and ERK1/2 cascades. Receptor activity is modulated by GRK2 and RGS proteins. In macrophages, EP3 expression is induced by PGE2 itself as well as by upstream pro-inflammatory mediators such as IL-1??, TNF-??, and LPS, often via NF-??B. Downstream, EP3 regulates effectors including cAMP, PKA, COX-2, RhoA, and transcriptional programs that control inflammatory cytokine production and phagocytosis.

In RAW 264.7 cells, Ptger3 knockout abrogates Gi-mediated inhibitory tone on adenylate cyclase, thereby disrupting PGE2-dependent modulation of macrophage function. This model is instrumental for deciphering EP3??s role in macrophage polarization, migration, and the balance between pro- and anti-inflammatory cytokine outputs. It provides a defined system to study the contribution of EP3 to diseases such as rheumatoid arthritis, asthma, colorectal cancer, atherosclerosis, and preterm labor.

Typical applications include measurement of cAMP levels, Western blotting for downstream effectors (e.g., phospho-ERK1/2, phospho-AKT), RT-qPCR for gene expression changes, ELISA-based cytokine profiling, phagocytosis and transwell migration assays, and flow cytometric analysis of surface markers. The line is also suited for NF-??B reporter studies and co-culture assays modeling the tumor microenvironment. For technical support and ordering details, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)